Thursday, October 05, 2017 12:25:21 PM
(In Sept. 29 story, corrects to say that Heplisav may be used by diabetics at risk of contracting Hepatitis B, instead of by diabetics who already have the virus, paragraph 8) By Carl O'Donnell Sept 29 (Reuters) - Dynavax Technologies Corporation <DVAX.O>, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said. The review is at an early stage and the company has made no commitment to conduct a sale or licensing process, the people said. The company may choose to go forward with its own commercial launch of the drug, they said this week. "We remain fully committed to preparing for a commercial launch in 2018," Dynavax spokesman Ryan Spencer told Reuters. "We continue to evaluate any interest from potential partners as part of our long-term strategic planning." A deal for the drug, called Heplisav, which is expected to receive regulatory approval later this year, would give Dynavax a cash infusion that it could use to finance its portfolio of cancer drugs under development. In July, a U.S. Food and Drug Administration panel green-lighted Dynavax's hepatitis B drug, a strong indication that it will be approved. Shares rose around 70 percent on the news and have continued to rise. Dynavax now trades at $21.50, more than twice its valuation before the FDA panel. Dynavax expects Heplisav to launch commercially early next year. Analysts expect the drug will quickly gain market share from its main rival, Engerix-B, made by GlaxoSmithKline <GSK.L>, because it is administered with fewer doses. It also expected to be more effective than its rivals on patients with type 2 diabetes, who are at elevated risk of contracting the hepatitis B virus. Meanwhile, Dynavax is working on several early-stage clinical trials on drugs that promise to use the body's own immune system to fight cancer. Dynavax's drugs modify immune cell receptors to make them more responsive to cancer cells. The company says that they have the potential to be used in combination with other novel cancer treatments, potentially tapping them into a large and lucrative market. Last month, biotech Gilead Sciences <GILD.O> agreed to acquire a cancer drug developer, Kite Pharma Inc <KITE.O> for $11.9 billion. Reuters previously reported that cancer drugmaker Tesaro Inc <TSRO.O>, another so-called immuno-oncology company, was mulling a potential sale after receiving inbound interest. (Reporting by Carl O'Donnell; Editing by James Dalgleish) ((Carl.ODonnell@thomsonreuters.com)(+1 646 223-6629;))
Recent DVAX News
- Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • PR Newswire (US) • 04/24/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 01:17:21 AM
- Dynavax to Present at TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/27/2024 11:54:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:10:48 PM
- Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance • PR Newswire (US) • 02/22/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:36:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:45:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:44:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:43:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:42:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:39:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:56:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:46:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:25:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:16:46 PM
- Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 • PR Newswire (US) • 02/08/2024 09:15:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 02/08/2024 01:41:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:45:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:33:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:32:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:31:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/19/2024 07:40:54 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:10:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM